Biosimilar and Follow-On Biologics Market Is Progressing Towards A Strong Growth By 2018


Posted November 15, 2016 by ranutmr

There is a rising demand for low cost biological drugs. Commercial and regulatory developments are taking the follow-on biologics market to new heights.

 
There is a rising demand for low cost biological drugs. Commercial and regulatory developments are taking the follow-on biologics market to new heights. Drug manufacturers are exploring the possibilities of producing generic biopharmaceuticals drugs with a motive of reducing the prices of these life saving drugs. However, these possibilities are opposed by some scientific challenges and unanswered questions.

Some of the major factors driving the market are rising healthcare cost, expensive drugs and the ageing population. The major challenges faced by the follow-on biologics market are risk factors as it requires high investment and possibilities of failure during the drug development stages. The growth potential for biologics market is expected to be strong in the upcoming years as patents for numerous second generation therapeutic proteins slated for expiry between 2013 and 2019.

For Any Queries Get Solutions With A PDF Sample : http://bit.ly/2f6KX8p

Many uncertainties surrounding the follow-on biologics are creating significant hurdles for companies to increase their business in the global market. The only way to success is to organize a cross disciplinary team with expertise in biological products, clinical development, regulatory affairs, and medical practices to watchfully plan a proper development strategy.

Follow-on Biologics Market Segmentation
Follow-on biologics market is segmented based on the biologic drug classes as follows:
• Peptides
• Recombinant Glycosylated Proteins
• Recombinant Non-glycosylated Proteins
• Others

The research report on follow-on biologics market analyzes the global market size, and provides overview of market figures. It also studies the overall market growth rate and current advancements in industry. This report analyzes current trends, Porter’s five force analysis, and complete profiles of top industry players. It also provides a detailed review of micro and macro factors essential for existing market players and new entrants along with value chain analysis.

Major geographies covered under this research report are North America, Europe, Asia-Pacific and the Rest of the World.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/biosimilar-and-follow-on-biologics-market.html

The key players dominating this market are 3SBio, Abbott, Abraxis BioScience, Alexion Pharmaceuticals, Amphastar Pharmaceuticals, Astra Zeneca, Avesta Biotherapeutics and Research (ABRPL), Avesthagen, Axicorp, Biogen Idec, Bristol-Myers Squibb, CCL Pharmaceuticals, CinnaGen, Cipla, Dr. Reddy’s Laboratories, Elan Corporation, Genentech, GlaxoSmithKline (GSK), Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Ranbaxy Laboratories, Sandoz, Zenotech, and others.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Transparency Market Research
Country United States
Categories Health , Marketing , Medical
Tags biosimilar market size , followon biologics market , followon biologics market share
Last Updated November 15, 2016